At a glance
- Originator Bristol-Myers Squibb
- Class Antidepressants; Antihypertensives; Antineoplastics
- Mechanism of Action Neuropeptide Y receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 18 Jan 2005 Discontinued - Preclinical for Depression in USA (unspecified route)
- 09 Feb 2001 Profile reviewed but no significant changes made
- 25 Aug 1998 No-Development-Reported for Depression in USA (Unknown route)